vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and ROGERS CORP (ROG). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $200.5M, roughly 1.0× ROGERS CORP). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 2.2%, a 6.0% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 5.2%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $1.1M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs -3.3%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
COLL vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $200.5M |
| Net Profit | $17.0M | $4.5M |
| Gross Margin | 62.5% | 32.2% |
| Operating Margin | 29.6% | — |
| Net Margin | 8.3% | 2.2% |
| Revenue YoY | 12.9% | 5.2% |
| Net Profit YoY | 35.3% | 421.4% |
| EPS (diluted) | $0.48 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $205.4M | $201.5M | ||
| Q3 25 | $209.4M | $216.0M | ||
| Q2 25 | $188.0M | $202.8M | ||
| Q1 25 | $177.8M | $190.5M | ||
| Q4 24 | $181.9M | $192.2M | ||
| Q3 24 | $159.3M | $210.3M | ||
| Q2 24 | $145.3M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $17.0M | $4.6M | ||
| Q3 25 | $31.5M | $8.6M | ||
| Q2 25 | $12.0M | $-73.6M | ||
| Q1 25 | $2.4M | $-1.4M | ||
| Q4 24 | $12.5M | $-500.0K | ||
| Q3 24 | $9.3M | $10.7M | ||
| Q2 24 | $19.6M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 62.5% | 31.5% | ||
| Q3 25 | 61.7% | 33.5% | ||
| Q2 25 | 57.7% | 31.6% | ||
| Q1 25 | 54.8% | 29.9% | ||
| Q4 24 | 54.0% | 32.1% | ||
| Q3 24 | 60.8% | 35.2% | ||
| Q2 24 | 62.5% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 29.6% | 3.5% | ||
| Q3 25 | 29.7% | 7.3% | ||
| Q2 25 | 18.7% | -33.3% | ||
| Q1 25 | 12.2% | -0.2% | ||
| Q4 24 | 20.9% | -6.6% | ||
| Q3 24 | 21.9% | 6.9% | ||
| Q2 24 | 32.7% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 8.3% | 2.3% | ||
| Q3 25 | 15.0% | 4.0% | ||
| Q2 25 | 6.4% | -36.3% | ||
| Q1 25 | 1.4% | -0.7% | ||
| Q4 24 | 6.9% | -0.3% | ||
| Q3 24 | 5.9% | 5.1% | ||
| Q2 24 | 13.5% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.48 | $0.20 | ||
| Q3 25 | $0.84 | $0.48 | ||
| Q2 25 | $0.34 | $-4.00 | ||
| Q1 25 | $0.07 | $-0.08 | ||
| Q4 24 | $0.36 | $-0.04 | ||
| Q3 24 | $0.27 | $0.58 | ||
| Q2 24 | $0.52 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $1.2B |
| Total Assets | $1.7B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $386.7M | $197.0M | ||
| Q3 25 | $285.9M | $167.8M | ||
| Q2 25 | $222.2M | $157.2M | ||
| Q1 25 | $197.8M | $175.6M | ||
| Q4 24 | $162.8M | $159.8M | ||
| Q3 24 | $120.0M | $146.4M | ||
| Q2 24 | $271.6M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $301.7M | $1.2B | ||
| Q3 25 | $274.8M | $1.2B | ||
| Q2 25 | $232.2M | $1.2B | ||
| Q1 25 | $234.4M | $1.3B | ||
| Q4 24 | $228.8M | $1.3B | ||
| Q3 24 | $234.3M | $1.3B | ||
| Q2 24 | $216.6M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.6B | $1.4B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.1B | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $5.8M |
| Free Cash FlowOCF − Capex | $122.4M | $1.1M |
| FCF MarginFCF / Revenue | 59.6% | 0.5% |
| Capex IntensityCapex / Revenue | 0.3% | 2.3% |
| Cash ConversionOCF / Net Profit | 7.25× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $123.0M | $46.9M | ||
| Q3 25 | $78.4M | $28.9M | ||
| Q2 25 | $72.4M | $13.7M | ||
| Q1 25 | $55.4M | $11.7M | ||
| Q4 24 | $84.6M | $33.7M | ||
| Q3 24 | $-9.0M | $42.4M | ||
| Q2 24 | $67.4M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $122.4M | $42.2M | ||
| Q3 25 | $78.3M | $21.2M | ||
| Q2 25 | $72.4M | $5.6M | ||
| Q1 25 | $54.6M | $2.1M | ||
| Q4 24 | $84.1M | $18.3M | ||
| Q3 24 | $-9.2M | $25.2M | ||
| Q2 24 | $67.1M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 59.6% | 20.9% | ||
| Q3 25 | 37.4% | 9.8% | ||
| Q2 25 | 38.5% | 2.8% | ||
| Q1 25 | 30.7% | 1.1% | ||
| Q4 24 | 46.2% | 9.5% | ||
| Q3 24 | -5.8% | 12.0% | ||
| Q2 24 | 46.2% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.3% | 2.3% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.4% | 5.0% | ||
| Q4 24 | 0.3% | 8.0% | ||
| Q3 24 | 0.2% | 8.2% | ||
| Q2 24 | 0.2% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 7.25× | 10.20× | ||
| Q3 25 | 2.49× | 3.36× | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | 3.96× | ||
| Q2 24 | 3.44× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
